Study of BL-B01D1 and immunotherapy for advanced bladder cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old
- You must be able to take care of yourself and be out of bed most of the day (ECOG 0-1)
- You must have advanced bladder cancer that has not been treated with whole-body therapy before
- You must have a stored tumor sample from a biopsy within the past 3 years, or agree to have a new biopsy
- You must not have certain serious health issues like heart, lung, autoimmune, or bleeding problems, or active infections such as hepatitis or HIV
- You must not be pregnant, and if you can have children, you need to use birth control during and for 6 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
This trial tests a new drug combination—BL-B01D1 plus a PD-1 immunotherapy—for people who have just been diagnosed with extensive-stage small cell lung cancer and have not had any prior treatment for it. The goal is to see if this combination can help shrink or control the cancer better than standard therapy.
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
This trial tests a new drug combination for people with cervical or endometrial cancer that has come back or spread. The study aims to see if adding BL-B01D1 to Keytruda (with or without Avastin) can help shrink tumors or slow the cancer's growth.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.